UiPath Inc. stocks have been trading up by 3.3 percent amid upbeat sentiment on its expanding AI automation capabilities.
Key Takeaways Traders Need To Know
- Q1 FY27 revenue came in around $418M, up 17% year over year and ahead of roughly $397.5M expectations, with PATH posting its first-ever GAAP operating profit and strong cash generation.
- Annual recurring revenue for UiPath reached about $1.901B, growing roughly 11–12% year over year, backed by a healthy 109% dollar-based net retention rate and $49M in net new ARR.
- Management nudged FY27 revenue guidance up to $1.776B–$1.781B and guided Q2 revenue to $395M–$400M, signaling steady growth and reinforcing confidence in PATH’s automation pipeline.
- Shares of PATH jumped roughly 4.5% to $12.10 after the Q1 print and guidance raise, while BofA lifted its target to $13 but kept an Underperform rating, waiting for faster ARR acceleration.
- UiPath expanded its AI automation footprint with its Maestro Case launch, a Dubai cloud security certification, and a high-impact Maestro deployment at One NZ that slashed provisioning times.
Live Update At 14:33:35 EDT: On Wednesday, June 24, 2026 UiPath Inc. stock [NYSE: PATH] is trending up by 3.3%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
PATH is trying to turn a choppy chart into a base. Over the last few weeks, UiPath has faded from a spike near $13.10 on 2026/06/01 down toward the $10–$10.50 zone, where the stock is now trying to stabilize. That pullback came even after PATH’s roughly 4.5% pop to $12.10 on its Q1 earnings beat and raised guidance, showing how quickly sentiment can cool in software names.
Recent daily candles around $10–$10.80 show tight ranges and smaller wicks. For active traders, that often signals consolidation after a big move, not outright breakdown. Today’s intraday action around $10.40–$10.55 also shows a controlled, low-volatility grind with repeated support near $10.38–$10.40 and sellers stepping in around $10.55.
More Breaking News
- HSCS Stock Slides As HeartSciences Wins Key European Patent
- AFRM Extends CPP Deal As Price Target And Charter Hopes Lift Momentum
- ACHR Stock Steadies As Traders Focus On Cash Runway
- Quantinuum QNT Jumps As HPE Taps It For Hybrid Quantum Push
Fundamentally, PATH is stronger than this sub-$11 price suggests. UiPath runs at about 83% gross margin, has turned its first GAAP operating profit, and throws off positive free cash flow of roughly $129M last quarter. Leverage is low, with total debt to equity at just 0.04 and a current ratio of 2.3, giving PATH plenty of balance sheet room to ride out volatility. For traders, that combination—high margin, improving profitability, and a compressed price-to-sales near 3.2—often sets up sharp sentiment reversals when the next catalyst hits.
Why Traders Are Watching PATH’s AI And Guidance
PATH’s latest Q1 FY27 print is the kind of report that forces traders to re-check their bias. UiPath delivered roughly $418M in revenue, up 17% year over year and well ahead of about $397.5M consensus. More important, PATH finally crossed the line into GAAP operating profitability, while still expanding non-GAAP margins and generating strong operating cash flow.
Yes, adjusted EPS at $0.15 was a penny shy of the $0.16 estimate. But the tape told you what mattered: revenue, ARR, and cash flow. UiPath reported annual recurring revenue of about $1.901B, growing roughly 12% with a 109% dollar-based net retention rate and $49M in net new ARR. Those are the metrics growth-focused traders usually prioritize, especially when a name like PATH has been punished for slowing momentum.
Management then added fuel by raising FY27 revenue guidance to $1.776B–$1.781B, ahead of both its prior range and Street numbers near $1.76B. Q2 guidance of $395M–$400M sits roughly in line to slightly above consensus and points to high-single-digit revenue growth ahead, with low double-digit ARR growth and further margin expansion anchored by UiPath’s “agentic AI” strategy.
The Street’s reaction has been mixed but leaning positive. PATH shares spiked about 4.5% to $12.10 after the report. BofA nudged its target from $12 to $13 but kept an Underperform rating, calling PATH a discounted, “show-me” story until ARR growth clearly accelerates. Meanwhile, CFRA remains constructive with a Buy, even after trimming its target to $13. Across the board, analysts acknowledge that UiPath’s AI-driven pipeline and hyperscaler partnerships are real; the debate is about how fast that shows up in ARR.
For short-term traders, that tension between improving fundamentals and cautious coverage often creates tradable swings. PATH has a clear earnings narrative, a visible AI product roadmap, and a base forming around $10. That makes every new deal, product launch, or guidance update a potential spark.
Conclusion
For active traders, PATH now looks like a transition story: from high-growth promise to disciplined, profitable automation platform. UiPath just posted its first GAAP operating profit, grew revenue 17% to around $418M, and lifted FY27 guidance while keeping ARR on a steady climb toward roughly $1.9B and beyond. The balance sheet is clean, margins are thick, and free cash flow is solid.
At the same time, the market is not giving PATH a free pass. The stock has slipped from the low-teens back into the $10 area even after its post-earnings bounce, and major Wall Street desks like BofA still sit at Underperform even as they raise price targets. That push-pull keeps volatility alive, which is exactly what short-term traders need.
On the growth side, UiPath is leaning hard into AI-native orchestration with Maestro and Maestro Case, while high-profile wins—like the Dubai Electronic Security Center certification and the One NZ deployment that cut provisioning from 10 days to under 10 minutes—give the story real-world proof. If those use cases scale, PATH’s ARR picture can look very different over the next few years.
The key is to trade the data, not the hype. Or as Tim Sykes likes to say, “Always focus on the best risk/reward setups, react to the price action, and never fall in love with a stock.” That mindset lines up with another core principle of disciplined trading: as millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. PATH is giving traders a fresh set of numbers and catalysts to react to—but the rules of disciplined trading still apply. This coverage is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply